| 1581 |
National Cancer Institute |
Html |
en |
Thyroid Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of thyroid cancer. |
| thyroid hormone | 0.462109 |
| thyroid cells | 0.459144 |
| thyroid hormone levels | 0.441028 |
| body | 0.475956 |
| thyroid nodules | 0.440882 |
| thyroid hormone replacement | 0.418097 |
| type | 0.402327 |
| PDQ cancer information | 0.417269 |
| clinical trial search | 0.44196 |
| clinical trials | 0.712208 |
| thyroid cancer spreads | 0.460066 |
| radioactive iodine therapy | 0.447344 |
| cancer information summary | 0.398763 |
| clinical trial | 0.54371 |
| thyroid disease | 0.440863 |
| patients | 0.405549 |
| fine-needle aspiration biopsy | 0.401121 |
| sentinel lymph node | 0.409752 |
| thyroid tumor | 0.430395 |
| lymph nodes | 0.45279 |
| thyroid cancer cells | 0.479847 |
| thyroid cancer treatment | 0.491155 |
| radiation therapy | 0.478836 |
| medullary thyroid cancer | 0.563411 |
| tyrosine kinase inhibitor | 0.42467 |
|
| thyroid scan | 0.39797 |
| treatment | 0.554504 |
| childhood thyroid cancer | 0.480138 |
| thyroid nodule | 0.461177 |
| follicular thyroid cells | 0.442093 |
| metastatic thyroid cancer | 0.461409 |
| healthy thyroid | 0.426685 |
| undifferentiated thyroid cancer | 0.481926 |
| thyroid cancer | 0.866042 |
| cancer cells | 0.55043 |
| thyroid tissue | 0.43819 |
| familial medullary thyroid | 0.436692 |
| anaplastic thyroid cancer | 0.503212 |
| National Cancer Institute | 0.411413 |
| Thyroid hormones | 0.426342 |
| external radiation therapy | 0.459156 |
| papillary thyroid cancers | 0.4232 |
| differentiated thyroid cancer | 0.481235 |
| thyroid uses iodine | 0.446079 |
| cancer clinical trials | 0.453504 |
| stage | 0.433394 |
| tumor | 0.440267 |
| cancer | 0.979846 |
| information | 0.45122 |
|
CLICK HERE |
| 1704 |
National Cancer Institute |
Html |
en |
Psychological Stress and Cancer |
A fact sheet that describes the effects of stress on the body, the results of research on the relationship between stress and cancer, and information about coping with stress. |
| Sood AK | 0.622496 |
| cancer treatment | 0.603243 |
| primary breast cancer | 0.597411 |
| Antoni MH | 0.570507 |
| human cancer cells | 0.605494 |
| family member | 0.588007 |
| psychological distress | 0.593032 |
| fact sheet | 0.615559 |
| mammary fat pads | 0.570769 |
| emotional pressure | 0.583244 |
| Health care providers | 0.574848 |
| risky behaviors | 0.581446 |
| cancer metastasis | 0.572171 |
| social support | 0.574381 |
| triple-negative breast cancer | 0.658004 |
| various psychological factors | 0.615469 |
| Lutgendorf SK | 0.681275 |
| cancer patients | 0.656706 |
| cancer survival | 0.572148 |
| stress cause cancer | 0.708673 |
| blood sugar levels | 0.578812 |
| Clinical Oncology | 0.599718 |
| speed heart rate | 0.575901 |
| ovarian carcinoma patients | 0.577415 |
|
| higher rates | 0.57609 |
| specific psychological conditions | 0.622117 |
| Psychological Bulletin | 0.579687 |
| elevated tumor norepinephrine | 0.576809 |
| psychological stress | 0.974362 |
| beta blockers | 0.5732 |
| normal life activities | 0.583211 |
| physical health problems | 0.585785 |
| drinking alcohol | 0.576593 |
| cancer outcomes | 0.570999 |
| biobehavioral signaling pathways | 0.570101 |
| stress management techniques | 0.670628 |
| clinical health psychologist | 0.575253 |
| Cancer Research | 0.5705 |
| stress hormone norepinephrine | 0.675379 |
| poorer clinical outcomes | 0.584728 |
| stress hormones | 0.675405 |
| people | 0.602029 |
| certain stress hormones | 0.663467 |
| New patient-centered care | 0.571423 |
| close family member | 0.58133 |
| Related Resources | 0.579385 |
| et al | 0.674807 |
| Related Resources section | 0.573303 |
|
CLICK HERE |
| 1729 |
National Cancer Institute |
Html |
en |
Hyperthermia in Cancer Treatment |
A fact sheet that defines hyperthermia (treating tumors with heat) and its side effects. |
| cancer treatment | 0.403898 |
| peritoneal cavity temperature | 0.426528 |
| External applicators | 0.382217 |
| whole-body hyperthermia | 0.729094 |
| van der Zee | 0.371709 |
| Clinical Radiation Oncology. | 0.380706 |
| tumor location | 0.365525 |
| regional hyperthermia | 0.5725 |
| hyperthermic peritoneal perfusion | 0.490656 |
| metastatic cancer | 0.36336 |
| Gibbs FA Jr | 0.369277 |
| normal tissues | 0.422996 |
| cancer therapy | 0.407309 |
| hyperthermia treatment | 0.61506 |
| bladder cancer | 0.363102 |
| Deep tissue approaches | 0.386891 |
| clinical trials | 0.532546 |
| DeVita VT Jr. | 0.371357 |
| interstitial hyperthermia | 0.571391 |
| hyperthermia | 0.901227 |
| tissue characteristics | 0.386571 |
| hot water blankets | 0.375371 |
| peritoneal cavity | 0.431179 |
| hyperthermia techniques | 0.560349 |
| radiation therapy | 0.457463 |
|
| high temperatures | 0.42664 |
| primary peritoneal mesothelioma | 0.407141 |
| local hyperthermia | 0.597761 |
| body cavity | 0.386007 |
| cancer cells | 0.536875 |
| anticancer drugs | 0.424955 |
| Cancer Information Service | 0.393124 |
| Libutti SK | 0.372166 |
| tumor size | 0.36657 |
| certain anticancer drugs | 0.383187 |
| B.C. Decker Inc. | 0.373174 |
| Samulski TV. Hyperthermia | 0.573888 |
| Numerous clinical trials | 0.395138 |
| Clinical Trials Information | 0.383207 |
| malignant peritoneal mesothelioma | 0.399886 |
| body tissue | 0.392759 |
| Regional perfusion techniques | 0.40208 |
| Bast RC Jr. | 0.371129 |
| stomach cancer | 0.363295 |
| tumor | 0.394758 |
| inserts small needles | 0.373242 |
| et al | 0.437187 |
| higher temperatures | 0.384967 |
| research studies | 0.385011 |
|
CLICK HERE |
| 1768 |
National Cancer Institute |
Html |
es |
Perjuicios por fumar cigarrillos y beneficios para la salud al dejar el hábito |
Hoja informativa que contiene una lista de algunas de las sustancias del humo de tabaco que causan cáncer y describe los problemas de salud causados por fumar y los beneficios de dejar el hábito. |
| Neck Cancer Epidemiology | 0.422589 |
| Mortality Weekly Report | 0.414031 |
| Human Services | 0.435201 |
| An emerging health | 0.441866 |
| Annual smoking-attributable mortality | 0.414117 |
| National Health Interview | 0.418634 |
| productivity losses—united states | 0.413073 |
| muertes prematuras | 0.445781 |
| Disease Control | 0.419031 |
| tabaco sustancias | 0.451048 |
| emerging health crisis | 0.417693 |
| promoting smoking | 0.427125 |
| Health Benefits | 0.414213 |
| Estados Unidos | 0.436732 |
| Health Behavior | 0.414461 |
| olor. fumar kreteks | 0.444861 |
| smoking cessation after | 0.432247 |
| PubMed Abstract | 0.980608 |
| smoking cessation | 0.497845 |
| Smokeless Tobacco | 0.414167 |
| Second-hand Tobacco Smoke | 0.420375 |
| International Journal | 0.420012 |
| Smoking as | 0.425711 |
| Tobacco Research | 0.428882 |
| United States | 0.434188 |
|
| British Medical Journal | 0.433726 |
| early stage lung | 0.412709 |
| Causa cánceres | 0.417577 |
| causa enfermedades | 0.437169 |
| ambiente causa | 0.426356 |
| tobacco smoking | 0.490331 |
| obstructiva crónica | 0.447997 |
| tobacco aqueous pH | 0.419205 |
| Eissenberg T | 0.417223 |
| ambiente causa enfermedades | 0.423335 |
| causa inflamación | 0.413975 |
| Maziak W | 0.417052 |
| Ward KD | 0.4175 |
| systematic review | 0.417039 |
| muerte prematura | 0.420666 |
| Chronic Disease Prevention | 0.413895 |
| Andrology Prevention Weeks | 0.412666 |
| emerging health risk | 0.421288 |
| Cancer Institute | 0.452427 |
| leucemia mieloide aguda | 0.439669 |
| neck cancer | 0.417125 |
| cuánta nicotina | 0.415037 |
| Public Health Service | 0.416067 |
| New England Journal | 0.413417 |
|
CLICK HERE |
| 1833 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores carcinoides gastrointestinales (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores carcinoides gastrointestinales. |
| metastatic carcinoid tumor | 0.417651 |
| carcinoides gi | 0.793345 |
| enfermedad cardÃaca carcinoide | 0.432281 |
| carcinoides duodenales | 0.478754 |
| células ec | 0.425941 |
| tracto gi | 0.460962 |
| Sin embargo | 0.46213 |
| tumores carcinoides gi | 0.491452 |
| PDQ Tumores neuroendocrinos | 0.416768 |
| imaging features with | 0.416291 |
| células neuroendocrinas gi | 0.414118 |
| marcadores carcinoides | 0.432817 |
| Exp Clin Cancer | 0.413418 |
| Cancer Res | 0.421273 |
| Res Clin Endocrinol | 0.414031 |
| Clin Gastroenterol | 0.414029 |
| sÃntomas carcinoides | 0.431545 |
| Pract Res Clin | 0.438075 |
| sÃndrome carcinoideo | 0.506176 |
| Clin Cancer Res | 0.414666 |
| patients with | 0.502884 |
| carcinoid tumors | 0.605663 |
| Best Pract Res | 0.431995 |
| Clin Endocrinol Metab | 0.422923 |
| carcinoid heart | 0.423722 |
|
| carcinoides celulares cse | 0.43559 |
| carcinoide celular cse | 0.415154 |
| tumores carcinoides | 0.966863 |
| neuroendocrine tumors | 0.59007 |
| TNE pancreáticos | 0.414445 |
| gastrointestinal tract | 0.419836 |
| tumores carcinoides gastrointestinales | 0.615452 |
| Surg Pathol | 0.422847 |
| Dig Dis Sci | 0.415197 |
| tumores tipo | 0.415164 |
| multiple endocrine neoplasia | 0.418143 |
| CSE tipo | 0.414261 |
| TNE GI | 0.460772 |
| tumores neuroendocrinos | 0.4479 |
| carcinoides esporádicos gi | 0.445952 |
| Surg Oncol | 0.418143 |
| with von recklinghausen | 0.424868 |
| somatostatin receptor | 0.413855 |
| neuroendocrine tumour | 0.454787 |
| tumores neuroendocrinos pancreáticos | 0.419002 |
| carcinoid tumor with | 0.413498 |
| Acad Sci | 0.415384 |
| gastrointestinal carcinoids | 0.415688 |
| tumores duodenales | 0.41576 |
|
CLICK HERE |
| 1949 |
National Cancer Institute |
Html |
es |
Tratamiento del linfoma relacionado con el sida (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del linfoma relacionado con el sida. |
| linfáticos afectados.ampliar linfoma | 0.30069 |
| estadio iiis+e | 0.227448 |
| células madre | 0.561403 |
| estadio iv | 0.248805 |
| siguientes elementos | 0.21398 |
| sudores nocturnos | 0.287643 |
| alto riesgo | 0.208757 |
| vÃa oral | 0.208173 |
| historial médico | 0.211748 |
| rayos x | 0.210669 |
| abdomen).ampliar linfoma | 0.262027 |
| estadio ie | 0.284505 |
| cáncer.ampliar aspiración | 0.213287 |
| lÃquido cefalorraquÃdeo | 0.384161 |
| punción espinal.Ampliar | 0.212727 |
| National Cancer Institute | 0.208952 |
| Instituto Nacional | 0.215593 |
| estadio iie | 0.283482 |
|
| PDQ Tratamiento | 0.219955 |
| segura medicamentos | 0.210953 |
| lÃquido incoloro | 0.216453 |
| siguientes biopsias | 0.213705 |
| estadio iiie | 0.319333 |
| siguientes problemas | 0.21343 |
| sistema nervioso central | 0.917575 |
| Physician Data Query | 0.232209 |
| cabo actividades | 0.210804 |
| ósea elabora glóbulos | 0.24265 |
| SNC).Ampliar Quimioterapia | 0.221029 |
| estadio iiis | 0.541053 |
| almacena células | 0.232785 |
| células b | 0.231648 |
| Estadio IIIE+S | 0.227106 |
| siguientes pruebas | 0.212565 |
| siguientes estadios | 0.212441 |
|
CLICK HERE |
| 1959 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de vagina (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de vagina. |
| parto).ampliar anatomÃa | 0.303951 |
| siguientes procedimientos | 0.324612 |
| siguientes aspectos | 0.303939 |
| pequeña cantidad | 0.302401 |
| estadio ii | 0.3299 |
| vÃa oral | 0.301938 |
| historial médico | 0.303531 |
| rayos x | 0.302933 |
| estadio ivb | 0.318379 |
| intensa luz | 0.302127 |
| Pap.Ampliar Prueba | 0.303248 |
| estadio iva | 0.313191 |
| National Cancer Institute | 0.301226 |
| realidad células | 0.307398 |
| vagina causa efectos | 0.315579 |
|
| sangrado anormal | 0.312233 |
| áreas anormales.ampliar examen | 0.305435 |
| Instituto Nacional | 0.302424 |
| PDQ Tratamiento | 0.308282 |
| presente sección | 0.301728 |
| Physician Data Query | 0.305028 |
| medicamento des | 0.324421 |
| prueba pap | 0.303798 |
| estadio iii | 0.307024 |
| pequeña incisión | 0.302169 |
| cuello uterino | 0.962189 |
| histerectomÃa abdominal | 0.303006 |
| procedimiento.ampliar ureteroscopÃa | 0.30314 |
| siguientes estadios | 0.303001 |
|
CLICK HERE |
| 2078 |
National Cancer Institute |
Html |
es |
Tomografía computarizada (TC) y exploraciones para cáncer |
Hoja informativa sobre el procedimiento y tecnología de la TC y sus usos para examen de detección, diagnóstico y tratamiento del cáncer. Hoja informativa 5.2s del Instituto Nacional del Cáncer. |
| imágenes llamada fdg | 0.212869 |
| hallazgos anómalos | 0.149049 |
| Pediatric Computed Tomography | 0.196499 |
| persona promedio | 0.156787 |
| Retrieved July | 0.224181 |
| rayos x | 0.774234 |
| from ct scans | 0.197405 |
| ACR Appropriateness Criteria® | 0.187415 |
| Patient Safety | 0.146744 |
| Low Levels | 0.215439 |
| Radiation Risks from | 0.30681 |
| radiation dose | 0.305638 |
| health care providers | 0.311726 |
| Lung Screening Trial | 0.175719 |
| risks from | 0.542401 |
| Assess Health Risks | 0.201898 |
| Retrieved June | 0.147049 |
| Exposición Innecesaria | 0.154118 |
| Internal Medicine | 0.215735 |
| Estados Unidos | 0.457591 |
| PubMed Abstract | 0.688591 |
| from ct | 0.241742 |
| mejores imágenes | 0.190153 |
| Cancer Imaging Program | 0.180886 |
| SEER Cancer Statistics | 0.179794 |
|
| Reducing Radiation from | 0.255009 |
| New Hampshire Avenue | 0.163654 |
| radiation risks | 0.481539 |
| alto riesgo | 0.166125 |
| Drug Administration | 0.216737 |
| British Medical Journal | 0.160951 |
| retrospective cohort study | 0.171194 |
| Mi Historia Médica | 0.162596 |
| lifetime attributable risk | 0.182458 |
| American College | 0.194044 |
| National Cancer Institute | 0.177442 |
| Health Risks from | 0.371263 |
| baja dosis | 0.918737 |
| dosis anual promedio | 0.421854 |
| from diagnostic imaging | 0.192917 |
| arteriopatÃa coronaria | 0.148972 |
| computed tomography | 0.455191 |
| Ionizing Radiation | 0.294632 |
| risks from exposure | 0.389205 |
| National Research Council | 0.163031 |
| pequeños riesgos | 0.152571 |
| Colegio Americano | 0.296344 |
| Estudio Nacional | 0.328775 |
| Sociedad Radiológica | 0.211562 |
|
CLICK HERE |
| 3876 |
National Cancer Institute |
Html |
en |
The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) |
Apply for the NCI F99/K00 Award that helps late-stage doctoral candidates finish their training and then transition into cancer-focused research positions. |
| K00 phase institution | 0.388613 |
| applicant institution | 0.265884 |
| Research Doctoral candidates | 0.275389 |
| Funding Opportunity Announcement | 0.903132 |
| research supplies | 0.244496 |
| Career Development Award | 0.350987 |
| k00 award | 0.331719 |
| Ph.D. dissertation requirements | 0.237088 |
| phase institutional representative | 0.335728 |
| project award period | 0.253621 |
| indirect costs | 0.425626 |
| NCI F99/K00 Predoc | 0.307817 |
| Institutional Allowance | 0.281782 |
| Career Development Support | 0.249362 |
| Research Career Development | 0.347168 |
| k00 phase | 0.762118 |
| Research Plan section | 0.261319 |
| career development skills | 0.241364 |
| health-related Ph.D. program | 0.243519 |
| F99 primary sponsor | 0.23706 |
| Research Service Award | 0.312163 |
| Individual Research Career | 0.265006 |
| mandatory NCI-sponsored conference | 0.307767 |
| Opportunity Announcement instructions | 0.260896 |
| career development research | 0.317687 |
|
| dissertation research project | 0.396866 |
| Ph.D. degree program | 0.256222 |
| valid U.S. visas | 0.237157 |
| Postdoctoral Fellow Transition | 0.248842 |
| Application Guide | 0.311615 |
| NCI Predoctoral | 0.237727 |
| F99 phase | 0.471921 |
| dissertation research training | 0.299174 |
| program staff | 0.238571 |
| Program Staff Contact | 0.236142 |
| Research Strategy | 0.247855 |
| F99/K00 Award | 0.359733 |
| F99 grant mechanism | 0.235643 |
| assigned NCI Program | 0.270275 |
| Development Award Supplemental | 0.254853 |
| F99 award | 0.269956 |
| fringe benefits | 0.272186 |
| valid U.S. visa | 0.254123 |
| career development | 0.562023 |
| Research Plan Sections | 0.252481 |
| Fellowship Applicant Section | 0.257658 |
| F99/K00 Award application | 0.300758 |
| health-related research field | 0.279872 |
| Postdoctoral Research Direction | 0.273719 |
|
CLICK HERE |
| 15738 |
National Cancer Institute |
Html |
en |
Financial Toxicity and Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the risk of experiencing financial difficulty during cancer treatment. |
| adult cancer survivors | 0.29753 |
| cancer treatment | 0.260149 |
| study | 0.333877 |
| high out-of-pocket spending | 0.29174 |
| health insurance | 0.332995 |
| newly diagnosed cancer | 0.254116 |
| out-of-pocket cost burden | 0.275794 |
| financial hardship | 0.814372 |
| colorectal cancer patients | 0.270243 |
| colorectal cancer survivors | 0.274934 |
| economic burden | 0.33821 |
| higher out-of-pocket spending | 0.308086 |
| Support Care Cancer | 0.263278 |
| material financial hardship | 0.310411 |
| Cancer Care Outcomes | 0.299421 |
| high out-of-pocket costs | 0.25691 |
| health care | 0.364957 |
| out-of-pocket health care | 0.305633 |
| higher out-of-pocket costs | 0.256873 |
| high out-of-pocket burden | 0.326935 |
| State cancer patients | 0.282656 |
| cancer care | 0.417219 |
| personal financial burden | 0.365783 |
| lung cancer patients | 0.262392 |
|
| ongoing cancer care | 0.28258 |
| colorectal cancer | 0.3351 |
| cancer patients | 0.489203 |
| Clin Oncol | 0.334879 |
| comprehensive cancer center | 0.290609 |
| cancer-related financial burden | 0.257868 |
| cancer diagnosis | 0.320181 |
| later financial hardship | 0.252008 |
| Long-term financial burden | 0.276409 |
| financial distress | 0.563858 |
| out-of-pocket spending | 0.410176 |
| breast cancer survivors | 0.328299 |
| financial burden | 0.630038 |
| out-of-pocket costs | 0.285058 |
| greater financial burden | 0.273818 |
| financial toxicity | 0.49873 |
| cancer survivors | 0.880073 |
| advanced-stage cancer patients | 0.289755 |
| high financial burden | 0.284717 |
| cancer | 0.949444 |
| substantial financial hardship | 0.256681 |
| risk | 0.255869 |
| cancer history | 0.289124 |
|
CLICK HERE |